Navigation Links
Orqis(R) Medical Awarded 15th U.S. Patent
Date:4/23/2008

Intellectual Property Expands to 41 Patents in more than 20 Countries

LAKE FOREST, Calif., April 23 /PRNewswire/ -- Orqis(R) Medical Corporation, a medical products company developing and marketing devices to improve cardiac performance through Aortic Flow Therapy, announced today that the United States Patent and Trademark Office has issued U.S. Patent number 7,331,921 (the '921 patent) entitled "Implantable Heart Assist System and Method of Applying Same." The '921 patent which discloses and claims methods and apparatus for intravascular renal (kidney) perfusion is exclusively owned by Orqis and is the Company's 15th U.S. Patent.

Mr. Ken Charhut, President and CEO, Orqis Medical, stated, "This latest patent is the result of Orqis' aggressive intellectual property strategy to treat the cardio-renal syndrome and improve cardiac performance with less invasive treatment approaches." He continued, "Orqis is developing a large intellectual property footprint that addresses the treatment gap between medical management and more invasive procedures without ever touching the heart."

Orqis' patent portfolio now encompasses 15 U.S. Patents and 26 International Patents in over 20 countries.

About Heart Failure

Over 5 million Americans suffer from heart failure, a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema. In the U.S., heart failure results in over 1 million hospitalizations annually and is responsible for over $33 billion in direct and indirect costs to the U.S. healthcare system each year.

About Orqis Medical Corporation

Orqis Medical Corporation is a privately held medical device company that develops and sells minimally invasive devices that improve cardiac performance through aortic flow therapy. Orqis devices uniquely bridge the treatment gap between medical management and more invasive procedures without ever touching the heart. The percutaneous Cancion System has secured the CE mark. The implantable Exeleras(R) System is in development.

For more information on Orqis Medical, please visit orqis.com

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.


'/>"/>
SOURCE Orqis Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Orqis(R) Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting
2. Best Practice Database Adds New Research on Effective Sales Force Incentives and Continuing Medical Education
3. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
4. Select Medical Corporation Makes Historic Multi-Million Dollar Gift to Harrisburg University
5. Developing roadmaps for enhancing the professional culture of medical schools
6. UT Southwestern Medical Center receives grant from the Robert Wood Johnson Foundation
7. The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues
8. Changes to Family and Medical Leave Act Clarify Employer Responsibilities
9. Medical Breakthrough Reaches America
10. CRH Medical Corporation opens third Center in Chicago
11. Medicare to consider public opinion about medical maggots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare Partners is ... continued efforts to provide innovative offerings to their healthcare partners. These solutions will ... dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding Talent Management ...
(Date:7/26/2017)... ... ... may be hard to imagine that the basic necessities that developed countries take for ... developed countries consider rare or eradicated, like measles, are still a rite of passage ... segment of "Success Files", actor Rob Lowe will introduce a new segment that will ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... will host its 2017 Process Validation and Process Validation Statistics Conferences in ... to process validation lifecycle challenges faced by process validation professionals and statisticians ...
(Date:7/26/2017)... Newport Beach, CA 92660 (PRWEB) , ... ... ... of Data Loss Prevention for on-premises, off and in the cloud ; today ... intelligent detection and scientific algorithms within a simple to use control console for ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with Six ... schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients ... will bring more Six Month Smiles patients to their providers.” , Each month, over ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... Mich. , July 13, 2017  Centurion Medical Products, a ... its DisImpactor ® fecal impaction removal device for hospice patient ... ... Patient pain management and ... for Hospice can help alleviate patient pain while preventing unneeded emergency ...
(Date:7/11/2017)... IRVINE, Calif. , July 11, 2017 Zymo Research Corp., ... new service that can quantify biological aging in a precise manner using ... Dr. Steve Horvath , a professor of human genetics and biostatistics ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... loci. ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
Breaking Medicine Technology: